Filter by tags: Radiopharmaceutical Neoplasm Clear all tag filters
4 news articles found
Germany-based radiopharmaceutical biotech company ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL) have launched Actineer, a joint venture for the industrial-scale production of actinium-225 (Ac-225).
- Source: World Nuclear News
- Date: Friday, 20 October 2023
- Original article: world-nuclear-news.org/Articles/CNL,-ITM-join-up-to-produce-rare-medical-radioisot
TerraPower Isotopes and Belgian joint venture PanTera have announced a collaboration to increase the global availability of actinium-225 (Ac-225), while Arizona-based Serva Energy has developed a new research reactor-based production method to ramp up the supply of the rare radioisotope.
- Source: World Nuclear News
- Date: Wednesday, 28 June 2023
- Original article: world-nuclear-news.org/Articles/Nuclear-innovation-companies-in-new-Ac-225-initiat
Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.
- Source: World Nuclear News
- Date: Thursday, 23 June 2022
- Original article: world-nuclear-news.org/Articles/Canadian-Candu-produces-cancer-therapy-isotope
The nuclear medicine sector is a small part of the wider nuclear industry, but it provides some of the most pioneering technologies in healthcare - and is close to making personalised medicine a reality. Antonis Kalemis, president of Nuclear Medicine Europe and business manager for molecular imaging at Siemens Healthineers, describes how nuclear medicine also tackles the most trenchant condition in modern healthcare: cancer.
- Source: World Nuclear News
- Date: Thursday, 29 July 2021
- Original article: world-nuclear-news.org/Articles/Viewpoint-Nuclear-medicine-is-crucial-for-fighting